3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
6
Sarcoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Thymoma
2
Rectal Neoplasms
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Leukemia, Myelomonocytic, Chronic
2
Esophageal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Interventions
pembrolizumab
26
Gemcitabine
20
Cisplatin
12
Nivolumab
11
Carboplatin
8
Paclitaxel
7
Docetaxel
7
atezolizumab
6
durvalumab
5
Radiotherapy
5
fludarabine
4
enfortumab vedotin
4
Ipilimumab
4
Cyclophosphamide
4
Vorinostat
3
Magnetic Resonance Spectroscopy
3
Fluorouracil
3
Filgrastim
3
Doxorubicin
3
zimberelimab
2
vocimagene amiretrorepvec
2
tremelimumab
2
romidepsin
2
poly ICLC
2
infigratinib
2
erdafitinib
2
cc-486
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urinary Bladder Neoplasms
×
Celecoxib
×
Clear all
NCT02885974
2025-07-28
BLAST
Baylor College of Medicine
Phase 1
Completed
22 enrolled